

Listing 16.2.6.5
Immunogenicity Results (Memory B Cells)

Part B

Randomi- sation Number	Group	Visit	MI TOTAL				MI IgG+	MI IgG+ stem	MI IgG+ NC99+	%stem cross	%NC99 cross	%CD27+Cd2 1-	%stem	Delta (D22-D1)	Fold (D22/D1)
			IgD- %	IgG%	IgA%	IgM%								MI IgG+	MI IgG+
B0011	Group B8	Day 1	0.05	0.0	61.5	15.4	0.000	0.000	0.00				0.16		
B0011	Group B8	Day 22	0.09	56.3	6.3	12.5	0.052	0.029	0.00	55.56	0.0	44.4	1.17	0.052	
B0014	Group B3	Day 1	0.02	46.7	40.0	0.0	0.011	0.002	0.00	14.29	0.0	14.3	0.14		
B0014	Group B3	Day 22	0.11	74.1	10.3	1.7	0.083	0.027	0.04	32.56	48.8	55.8	0.31	0.072	7.332
B0015	Group B9	Day 1	0.03	37.5	50.0	0.0	0.011	0.004	0.00	33.33	0.0	0.0	0.29		
B0015	Group B9	Day 22	0.42	96.7	1.6	0.8	0.402	0.068	0.00	16.81	0.0	27.7	0.52	0.391	36.902
B0017	Group B7	Day 1	0.05	83.7	9.3	2.3	0.045	0.001	0.00	2.78	0.0	0.0	0.13		
B0017	Group B7	Day 22	0.07	69.6	23.9	0.0	0.047	0.003	0.00	6.25	0.0	9.4	0.14	0.001	1.031
B0018	Group B9	Day 1	0.04	56.0	32.0	8.0	0.024	0.005	0.00	21.43	0.0	0.0	0.20		
B0018	Group B9	Day 22	0.69	80.5	8.4	1.3	0.553	0.023	0.01	4.18	1.7	35.6	0.19	0.529	22.983
B0021	Group B7	Day 1	0.23	83.7	6.1	0.0	0.195	0.005	0.01	2.44	7.3	0.0	0.27		
B0021	Group B7	Day 22	0.22	67.3	9.6	0.0	0.150	0.017	0.00	11.43	2.9	2.9	0.22	-0.046	0.766
B0023	Group B3	Day 1	0.08	64.5	12.9	16.1	0.051	0.008	0.00	15.00	0.0	25.0	0.12		
B0023	Group B3	Day 22	7.45	50.7	3.3	0.6	3.777	0.063	0.02	1.67	0.6	67.2	0.33	3.726	73.615
B0025	Group B8	Day 1	0.14	83.3	10.2	2.8	0.116	0.006	0.00	5.56	2.2	3.3	0.19		
B0025	Group B8	Day 22	0.50	91.3	5.7	1.7	0.456	0.023	0.01	5.15	2.2	27.2	0.21	0.339	3.913

Administration Site Key: FA = Forearm; UA= Upper arm

Treatments Part A: A1 = A/Sing MAP, 15 ug (FA); A2 = Afluria Quad IM (UA), 15 ug; A3 = Placebo MAP (FA); A4 = A/Sing Mono IM, 15 ug (UA)

Treatments Part B: B1 = A/Sing MAP, 15 ug (FA) with biopsy; B2 = Placebo MAP (FA) with biopsy

B3 = A/Sing MAP, 15 ug (FA); B4 = A/Sing MAP, 10 ug (FA); B5 = A/Sing MAP, 5 ug (FA); B6 = A/Sing MAP, 2.5 ug (FA)

B7 = Placebo MAP (FA); B8 = A/Sing MAP, 15 ug (UA); B9 = A/Sing IM, 15 ug, as 2018 Afluria Quad (UA)

Listing 16.2.6.5
Immunogenicity Results (Memory B Cells)

Part B

Randomi- sation Number	Group	Visit	MI TOTAL		IgA%	IgM%	MI IgG+	MI IgG+ stem	MI IgG+ NC99+	%stem cross	%NC99 cross	%CD27+Cd2 1-	%stem	Delta (D22-D1)	Fold (D22/D1)
			IgD- %	IgG%										MI IgG+	MI IgG+
B0026	Group B9	Day 1	0.03	63.6	18.2	9.1	0.017	0.005	0.00	28.57	14.3	14.3	0.17		
B0026	Group B9	Day 22	0.50	87.7	0.9	3.2	0.439	0.302	0.03	68.91	7.8	51.8	1.10	0.422	26.124
B0027	Group B3	Day 1	0.05	20.0	20.0	10.0	0.010	0.000	0.00	0.00	0.0	0.0	0.10		
B0027	Group B3	Day 22	0.96	81.4	4.9	0.5	0.781	0.084	0.02	10.74	2.7	55.7	0.70	0.771	79.688
B0030	Group B7	Day 1	0.05	62.5	25.0	4.2	0.032	0.000	0.00	0.00	6.7	6.7	0.11		
B0030	Group B7	Day 22	0.08	65.2	13.0	4.3	0.055	0.011	0.00	20.00	0.0	20.0	0.08	0.023	1.728
B0034	Group B8	Day 1	0.06	46.7	6.7	13.3	0.029	0.017	0.00	57.14	0.0	14.3	0.27		
B0034	Group B8	Day 22	0.29	86.3	6.3	7.5	0.251	0.113	0.00	44.93	1.4	44.9	0.71	0.222	8.623
B0035	Group B9	Day 1	0.05	58.3	25.0	0.0	0.028	0.008	0.00	28.57	14.3	0.0	0.21		
B0035	Group B9	Day 22	0.13	92.3	5.8	1.9	0.118	0.015	0.00	12.50	0.0	45.8	0.41	0.090	4.211
B0036	Group B7	Day 1	0.06	74.2	12.9	9.7	0.046	0.006	0.00	13.04	0.0	0.0	0.24		
B0036	Group B7	Day 22	0.08	55.9	14.7	26.5	0.042	0.007	0.00	15.79	10.5	15.8	0.19	-0.004	0.911
B0038	Group B3	Day 1	0.06	81.8	18.2	0.0	0.049	0.011	0.00	22.22	0.0	11.1	0.22		
B0038	Group B3	Day 22	0.44	53.3	2.9	42.9	0.234	0.050	0.00	21.43	0.0	78.6	0.53	0.185	4.740
B0039	Group B7	Day 1	0.05	100.0	0.0	0.0	0.045	0.012	0.00	26.67	0.0	0.0	0.24		

Administration Site Key: FA = Forearm; UA= Upper arm

Treatments Part A: A1 = A/Sing MAP, 15 ug (FA); A2 = Afluria Quad IM (UA), 15 ug; A3 = Placebo MAP (FA); A4 = A/Sing Mono IM, 15 ug (UA)

Treatments Part B: B1 = A/Sing MAP, 15 ug (FA) with biopsy; B2 = Placebo MAP (FA) with biopsy

B3 = A/Sing MAP, 15 ug (FA); B4 = A/Sing MAP, 10 ug (FA); B5 = A/Sing MAP, 5 ug (FA); B6 = A/Sing MAP, 2.5 ug (FA)

B7 = Placebo MAP (FA); B8 = A/Sing MAP, 15 ug (UA); B9 = A/Sing IM, 15 ug, as 2018 Afluria Quad (UA)

Listing 16.2.6.5
Immunogenicity Results (Memory B Cells)

Part B

Randomi- sation Number	Group	Visit	MI TOTAL		IgA%	IgM%	MI IgG+	MI IgG+	MI IgG+	%stem cross	%NC99 cross	%CD27+Cd2 1-	%stem	Delta (D22-D1)	Fold (D22/D1)
			IgD- %	IgG%				stem	NC99+					MI IgG+	MI IgG+
B0039	Group B7	Day 22	0.05	82.4	5.9	0.0	0.037	0.008	0.00	21.43	0.0	7.1	0.14	-0.008	0.826
B0040	Group B9	Day 1	0.04	0.0	25.0	50.0	0.000	0.000	0.00				0.25		
B0040	Group B9	Day 22	1.28	96.6	0.0	0.8	1.233	0.182	0.02	14.78	1.7	71.3	0.62	1.233	
B0041	Group B3	Day 1	0.56	86.7	8.5	1.8	0.485	0.014	0.04	2.80	7.7	53.8	0.41		
B0041	Group B3	Day 22	0.47	81.8	13.1	1.1	0.388	0.030	0.02	7.64	4.9	47.9	0.37	-0.097	0.801
B0043	Group B8	Day 1	0.04	88.9	5.6	0.0	0.039	0.000	0.00	0.00	6.3	0.0	0.14		
B0043	Group B8	Day 22	2.32	89.9	7.3	0.3	2.082	0.078	0.03	3.76	1.2	65.8	0.22	2.044	53.966
B0046	Group B7	Day 1	0.06	47.1	29.4	0.0	0.028	0.000	0.00	0.00	0.0	12.5	0.14		
B0046	Group B7	Day 22	0.06	85.0	5.0	5.0	0.054	0.003	0.00	5.88	0.0	0.0	0.13	0.026	1.916
B0047	Group B9	Day 1	0.05	62.5	4.2	25.0	0.032	0.000	0.00	0.00	0.0	13.3	0.13		
B0047	Group B9	Day 22	0.43	92.7	2.2	3.2	0.397	0.026	0.00	6.55	0.3	57.2	0.26	0.365	12.264
B0050	Group B8	Day 1	0.07	87.5	0.0	0.0	0.057	0.005	0.01	9.52	9.5	0.0	0.18		
B0050	Group B8	Day 22	1.82	98.2	1.4	0.2	1.783	0.083	0.03	4.67	1.6	54.2	0.41	1.726	31.135
B0051	Group B3	Day 1	0.03	36.4	36.4	0.0	0.013	0.003	0.00	25.00	25.0	0.0	0.20		
B0051	Group B3	Day 22	0.35	91.9	5.4	0.9	0.321	0.057	0.01	17.65	3.9	71.6	0.38	0.308	25.425

Administration Site Key: FA = Forearm; UA= Upper arm

Treatments Part A: A1 = A/Sing MAP, 15 ug (FA); A2 = Afluria Quad IM (UA), 15 ug; A3 = Placebo MAP (FA); A4 = A/Sing Mono IM, 15 ug (UA)

Treatments Part B: B1 = A/Sing MAP, 15 ug (FA) with biopsy; B2 = Placebo MAP (FA) with biopsy

B3 = A/Sing MAP, 15 ug (FA); B4 = A/Sing MAP, 10 ug (FA); B5 = A/Sing MAP, 5 ug (FA); B6 = A/Sing MAP, 2.5 ug (FA)

B7 = Placebo MAP (FA); B8 = A/Sing MAP, 15 ug (UA); B9 = A/Sing IM, 15 ug, as 2018 Afluria Quad (UA)

Listing 16.2.6.5
Immunogenicity Results (Memory B Cells)

Part B

Randomi- sation Number	Group	Visit	MI TOTAL		IgA%	IgM%	MI IgG+	MI IgG+ stem	MI IgG+ NC99+	%stem cross	%NC99 cross	%CD27+Cd2 1-	%stem	Delta (D22-D1)	Fold (D22/D1)
			IgD- %	IgG%										MI IgG+	MI IgG+
B0055	Group B8	Day 1	0.11	82.4	11.8	5.9	0.089	0.019	0.01	21.43	7.1	21.4	0.11		
B0055	Group B8	Day 22	1.06	85.3	6.8	2.6	0.908	0.033	0.14	3.68	15.3	77.3	0.19	0.819	10.228
B0056	Group B3	Day 1	0.01	100.0	0.0	0.0	0.011	0.000	0.00	0.00	0.0	0.0	0.04		
B0056	Group B3	Day 22	2.75	86.0	9.8	2.5	2.368	0.139	0.03	5.86	1.4	74.0	0.47	2.357	211.085
B0058	Group B9	Day 1	0.05	66.7	26.7	0.0	0.031	0.009	0.01	30.00	30.0	10.0	0.11		
B0058	Group B9	Day 22	1.59	82.1	16.7	0.2	1.305	0.079	0.05	6.02	4.2	66.0	0.31	1.274	42.634
B0059	Group B7	Day 1	0.11	93.5	4.3	2.2	0.102	0.021	0.01	20.93	11.6	2.3	0.19		
B0059	Group B7	Day 22	0.08	88.1	4.8	2.4	0.066	0.004	0.01	5.41	10.8	5.4	0.12	-0.036	0.650
B0060	Group B3	Day 1	0.07	66.7	0.0	11.1	0.046	0.000	0.00	0.00	0.0	0.0	0.13		
B0060	Group B3	Day 22	2.73	81.0	17.1	0.3	2.214	0.115	0.05	5.18	2.4	54.2	0.26	2.167	47.814
B0061	Group B8	Day 1	0.04	47.1	23.5	23.5	0.020	0.002	0.00	12.50	0.0	12.5	0.15		
B0061	Group B8	Day 22	2.16	95.7	3.9	0.4	2.065	0.357	0.20	17.31	9.7	79.6	1.19	2.045	104.888
B0063	Group B7	Day 1	0.04	40.0	13.3	40.0	0.016	0.000	0.00	0.00	16.7	33.3	0.05		
B0063	Group B7	Day 22	0.03	41.7	8.3	25.0	0.014	0.000	0.01	0.00	60.0	0.0	0.09	-0.001	0.908
B0064	Group B9	Day 1	0.04	70.6	5.9	11.8	0.026	0.000	0.00	0.00	8.3	25.0	0.11		
B0064	Group B9	Day 22	0.54	92.9	4.1	0.0	0.499	0.011	0.00	2.19	0.5	38.8	0.08	0.473	19.038

Administration Site Key: FA = Forearm; UA= Upper arm

Treatments Part A: A1 = A/Sing MAP, 15 ug (FA); A2 = Afluria Quad IM (UA), 15 ug; A3 = Placebo MAP (FA); A4 = A/Sing Mono IM, 15 ug (UA)

Treatments Part B: B1 = A/Sing MAP, 15 ug (FA) with biopsy; B2 = Placebo MAP (FA) with biopsy

B3 = A/Sing MAP, 15 ug (FA); B4 = A/Sing MAP, 10 ug (FA); B5 = A/Sing MAP, 5 ug (FA); B6 = A/Sing MAP, 2.5 ug (FA)

B7 = Placebo MAP (FA); B8 = A/Sing MAP, 15 ug (UA); B9 = A/Sing IM, 15 ug, as 2018 Afluria Quad (UA)

Listing 16.2.6.5
Immunogenicity Results (Memory B Cells)

Part B

Randomi- sation Number	Group	Visit	MI TOTAL		IgA%	IgM%	MI IgG+	MI IgG+ stem	MI IgG+ NC99+	%stem cross	%NC99 cross	%CD27+Cd2 1-	%stem	Delta (D22-D1)	Fold (D22/D1)
			IgD- %	IgG%										MI IgG+	MI IgG+
B0067	Group B8	Day 1	0.37	96.5	3.5	0.0	0.355	0.013	0.01	3.61	2.4	8.4	0.13		
B0067	Group B8	Day 22	0.92	98.6	1.4	0.0	0.907	0.047	0.01	5.21	1.4	48.3	0.10	0.552	2.554
B0069	Group B7	Day 1	0.04	76.9	23.1	0.0	0.032	0.000	0.00	0.00	0.0	0.0	0.05		
B0069	Group B7	Day 22	0.05	71.4	14.3	0.0	0.036	0.007	0.01	20.00	30.0	30.0	0.10	0.004	1.123
B0070	Group B9	Day 1	0.06	81.5	7.4	3.7	0.053	0.002	0.00	4.55	9.1	0.0	0.11		
B0070	Group B9	Day 22	2.10	93.4	5.3	0.6	1.957	0.070	0.06	3.60	2.9	69.3	0.26	1.904	37.253
B0072	Group B3	Day 1	0.10	87.5	0.0	6.3	0.091	0.033	0.01	35.71	14.3	0.0	0.16		
B0072	Group B3	Day 22	1.51	92.9	6.8	0.4	1.406	0.373	0.15	26.54	10.4	73.1	1.61	1.314	15.375
B0074	Group B9	Day 1	0.11	56.3	31.3	9.4	0.061	0.003	0.01	5.56	16.7	11.1	0.10		
B0074	Group B9	Day 22	1.12	78.0	17.4	2.6	0.876	0.020	0.02	2.23	2.6	52.4	0.12	0.815	14.333
B0075	Group B3	Day 1	0.08	71.0	16.1	3.2	0.057	0.005	0.00	9.09	0.0	4.5	0.11		
B0075	Group B3	Day 22	2.74	84.7	10.2	1.3	2.319	0.129	0.14	5.56	6.0	63.5	0.49	2.262	40.468
B0078	Group B8	Day 1	0.07	78.1	0.0	6.3	0.057	0.011	0.02	20.00	28.0	16.0	0.22		
B0078	Group B8	Day 22	3.39	95.6	2.3	0.1	3.245	0.327	0.11	10.09	3.5	67.6	1.38	3.187	56.698
B0082	Group B3	Day 1	0.07	68.4	0.0	15.8	0.045	0.027	0.01	61.54	23.1	23.1	0.19		

Administration Site Key: FA = Forearm; UA= Upper arm

Treatments Part A: A1 = A/Sing MAP, 15 ug (FA); A2 = Afluria Quad IM (UA), 15 ug; A3 = Placebo MAP (FA); A4 = A/Sing Mono IM, 15 ug (UA)

Treatments Part B: B1 = A/Sing MAP, 15 ug (FA) with biopsy; B2 = Placebo MAP (FA) with biopsy

B3 = A/Sing MAP, 15 ug (FA); B4 = A/Sing MAP, 10 ug (FA); B5 = A/Sing MAP, 5 ug (FA); B6 = A/Sing MAP, 2.5 ug (FA)

B7 = Placebo MAP (FA); B8 = A/Sing MAP, 15 ug (UA); B9 = A/Sing IM, 15 ug, as 2018 Afluria Quad (UA)

Listing 16.2.6.5
Immunogenicity Results (Memory B Cells)

Part B

Randomi- sation Number	Group	Visit	MI TOTAL		IgA%	IgM%	MI IgG+	MI IgG+ stem	MI IgG+ NC99+	%stem cross	%NC99 cross	%CD27+Cd2 1-	%stem	Delta (D22-D1)	Fold (D22/D1)
			IgD- %	IgG%										MI IgG+	MI IgG+
B0082	Group B3	Day 22	0.04	64.3	14.3	21.4	0.028	0.013	0.01	44.44	22.2	22.2	0.11	-0.016	0.638
B0083	Group B8	Day 1	0.05	75.8	15.2	0.0	0.037	0.000	0.00	0.00	0.0	0.0	0.17		
B0083	Group B8	Day 22	0.95	93.0	4.2	0.8	0.887	0.039	0.04	4.38	4.0	56.8	0.24	0.850	23.864
B0086	Group B9	Day 1	0.02	50.0	0.0	50.0	0.010	0.000	0.01	0.00	100.0	100.0	0.03		
B0086	Group B9	Day 22	0.69	87.7	1.5	3.1	0.602	0.549	0.02	91.23	3.5	64.9	1.65	0.592	63.160
B0087	Group B7	Day 1	0.04	69.6	30.4	0.0	0.031	0.006	0.00	18.75	0.0	18.8	0.10		
B0087	Group B7	Day 22	0.04	60.9	34.8	4.3	0.026	0.002	0.00	7.14	14.3	28.6	0.11	-0.005	0.852
B0088	Group B9	Day 1	0.05	69.2	19.2	7.7	0.034	0.008	0.01	22.22	27.8	5.6	0.09		
B0088	Group B9	Day 22	0.81	95.9	3.2	0.5	0.773	0.022	0.14	2.86	17.9	72.6	0.11	0.739	22.672
B0091	Group B8	Day 1	0.05	69.2	15.4	11.5	0.034	0.006	0.00	16.67	0.0	0.0	0.12		
B0091	Group B8	Day 22	5.65	78.8	10.3	7.9	4.452	0.405	0.02	9.09	0.5	52.7	1.03	4.418	130.309
B0093	Group B7	Day 1	0.03	0.0	66.7	0.0	0.000	0.000	0.00				0.11		
B0093	Group B7	Day 22	0.04	25.0	25.0	25.0	0.010	0.000	0.01	0.00	100.0	0.0	0.08	0.010	
B0094	Group B3	Day 1	0.03	76.9	7.7	7.7	0.023	0.005	0.01	20.00	30.0	20.0	0.14		
B0094	Group B3	Day 22	0.56	95.0	3.4	0.0	0.535	0.136	0.07	25.41	13.4	79.2	0.69	0.512	23.022

Administration Site Key: FA = Forearm; UA= Upper arm

Treatments Part A: A1 = A/Sing MAP, 15 ug (FA); A2 = Afluria Quad IM (UA), 15 ug; A3 = Placebo MAP (FA); A4 = A/Sing Mono IM, 15 ug (UA)

Treatments Part B: B1 = A/Sing MAP, 15 ug (FA) with biopsy; B2 = Placebo MAP (FA) with biopsy

B3 = A/Sing MAP, 15 ug (FA); B4 = A/Sing MAP, 10 ug (FA); B5 = A/Sing MAP, 5 ug (FA); B6 = A/Sing MAP, 2.5 ug (FA)

B7 = Placebo MAP (FA); B8 = A/Sing MAP, 15 ug (UA); B9 = A/Sing IM, 15 ug, as 2018 Afluria Quad (UA)

Listing 16.2.6.5
Immunogenicity Results (Memory B Cells)

Part B

Randomi- sation Number	Group	Visit	MI TOTAL				MI IgG+	MI IgG+ stem	MI IgG+ NC99+	%stem cross	%NC99 cross	%CD27+Cd2 1-	%stem	Delta (D22-D1)	Fold (D22/D1)
			IgD- %	IgG%	IgA%	IgM%								MI IgG+	MI IgG+
B0095	Group B9	Day 1	0.04	64.3	32.1	0.0	0.028	0.005	0.01	16.67	38.9	0.0	0.10		
B0095	Group B9	Day 22	0.16	78.2	9.7	4.0	0.127	0.021	0.02	16.49	19.6	34.0	0.15	0.098	4.494
B0098	Group B7	Day 1	0.06	42.1	21.1	26.3	0.023	0.015	0.00	62.50	12.5	25.0	0.14		
B0098	Group B7	Day 22	0.08	50.0	30.0	20.0	0.039	0.000	0.00	0.00	0.0	0.0	0.05	0.016	1.681
B0100	Group B8	Day 1	0.05	65.0	30.0	5.0	0.033	0.008	0.00	23.08	0.0	0.0	0.16		
B0100	Group B8	Day 22	0.35	76.1	13.0	0.7	0.268	0.020	0.01	7.62	4.8	40.0	0.12	0.234	8.050
B0101	Group B3	Day 1	0.08	56.5	34.8	8.7	0.045	0.007	0.00	15.38	7.7	7.7	0.10		
B0101	Group B3	Day 22	0.09	64.5	29.0	6.5	0.058	0.023	0.01	40.00	10.0	15.0	0.16	0.014	1.313
B0102	Group B8	Day 1	0.12	43.7	25.3	13.8	0.052	0.025	0.00	47.37	5.3	15.8	0.19		
B0102	Group B8	Day 22	2.98	80.7	17.3	0.9	2.404	0.150	0.10	6.26	4.3	41.4	0.32	2.351	45.875
B0104	Group B3	Day 1	0.03	65.0	25.0	5.0	0.022	0.005	0.00	23.08	15.4	0.0	0.10		
B0104	Group B3	Day 22	1.05	93.8	5.7	0.1	0.983	0.058	0.15	5.85	14.8	67.2	0.19	0.962	45.215
B0105	Group B9	Day 1	0.06	44.9	34.7	14.3	0.028	0.013	0.01	45.45	22.7	4.5	0.13		
B0105	Group B9	Day 22	0.18	74.2	19.4	1.6	0.134	0.032	0.03	23.91	19.6	58.7	0.17	0.106	4.821
B0108	Group B7	Day 1	0.09	56.3	34.4	0.0	0.053	0.006	0.00	11.11	0.0	16.7	0.13		
B0108	Group B7	Day 22	0.86	2.6	11.3	2.3	0.022	0.008	0.00	37.50	12.5	0.0	0.34	-0.031	0.417

Administration Site Key: FA = Forearm; UA= Upper arm

Treatments Part A: A1 = A/Sing MAP, 15 ug (FA); A2 = Afluria Quad IM (UA), 15 ug; A3 = Placebo MAP (FA); A4 = A/Sing Mono IM, 15 ug (UA)

Treatments Part B: B1 = A/Sing MAP, 15 ug (FA) with biopsy; B2 = Placebo MAP (FA) with biopsy

B3 = A/Sing MAP, 15 ug (FA); B4 = A/Sing MAP, 10 ug (FA); B5 = A/Sing MAP, 5 ug (FA); B6 = A/Sing MAP, 2.5 ug (FA)

B7 = Placebo MAP (FA); B8 = A/Sing MAP, 15 ug (UA); B9 = A/Sing IM, 15 ug, as 2018 Afluria Quad (UA)

Listing 16.2.6.5
Immunogenicity Results (Memory B Cells)

Part B

Randomi- sation Number	Group	Visit	MI TOTAL		IgA%	IgM%	MI IgG+	MI IgG+ stem	MI IgG+ NC99+	%stem cross	%NC99 cross	%CD27+Cd2 1-	%stem	Delta (D22-D1)	Fold (D22/D1)
			IgD- %	IgG%										MI IgG+	MI IgG+
B0110	Group B3	Day 1	0.06	73.9	17.4	4.3	0.047	0.014	0.00	29.41	0.0	0.0	0.08		
B0110	Group B3	Day 22	1.04	93.7	1.5	0.3	0.972	0.034	0.02	3.50	1.9	42.0	0.10	0.925	20.488
B0111	Group B8	Day 1	0.02	28.6	42.9	14.3	0.005	0.000	0.00	0.00	0.0	0.0	0.02		
B0111	Group B8	Day 22	0.16	93.3	3.3	0.0	0.150	0.003	0.02	1.79	10.7	32.1	0.09	0.145	31.369
B0114	Group B7	Day 1	0.05	16.7	25.0	8.3	0.008	0.004	0.00	50.00	0.0	0.0	0.03		
B0114	Group B7	Day 22	0.04	71.4	42.9	0.0	0.031	0.006	0.00	20.00	0.0	0.0	0.04	0.023	3.892
B0115	Group B9	Day 1	0.02	33.3	66.7	0.0	0.007	0.000	0.00	0.00	0.0	0.0	0.04		
B0115	Group B9	Day 22	0.87	57.7	1.8	10.8	0.504	0.118	0.02	23.44	3.1	42.2	0.34	0.497	68.286
B0116	Group B7	Day 1	0.20	74.5	3.9	3.9	0.151	0.012	0.01	7.89	5.3	5.3	0.03		
B0116	Group B7	Day 22	0.32	85.9	7.8	1.6	0.278	0.015	0.02	5.45	5.5	21.8	0.05	0.127	1.836
B0117	Group B9	Day 1	0.13	78.5	15.4	0.8	0.099	0.023	0.01	23.53	5.9	2.0	0.11		
B0117	Group B9	Day 22	0.39	91.3	6.7	0.3	0.353	0.034	0.03	9.52	9.5	23.4	0.14	0.254	3.561
B0120	Group B3	Day 1	0.05	31.6	42.1	21.1	0.016	0.000	0.00	0.00	0.0	0.0	0.09		
B0120	Group B3	Day 22	7.95	61.9	28.4	2.5	4.924	0.279	0.04	5.66	0.8	37.0	1.72	4.908	303.780
B0121	Group B8	Day 1	0.00				0.000	0.000	0.00				0.03		

Administration Site Key: FA = Forearm; UA= Upper arm

Treatments Part A: A1 = A/Sing MAP, 15 ug (FA); A2 = Afluria Quad IM (UA), 15 ug; A3 = Placebo MAP (FA); A4 = A/Sing Mono IM, 15 ug (UA)

Treatments Part B: B1 = A/Sing MAP, 15 ug (FA) with biopsy; B2 = Placebo MAP (FA) with biopsy

B3 = A/Sing MAP, 15 ug (FA); B4 = A/Sing MAP, 10 ug (FA); B5 = A/Sing MAP, 5 ug (FA); B6 = A/Sing MAP, 2.5 ug (FA)

B7 = Placebo MAP (FA); B8 = A/Sing MAP, 15 ug (UA); B9 = A/Sing IM, 15 ug, as 2018 Afluria Quad (UA)

Listing 16.2.6.5
Immunogenicity Results (Memory B Cells)

Part B

Randomi- sation Number	Group	Visit	MI TOTAL				MI IgG+	MI IgG+	%stem	%NC99	%CD27+Cd2	%stem	Delta (D22-D1)	Fold (D22/D1)
			IgD- %	IgG%	IgA%	IgM%							MI IgG+	MI IgG+
B0121	Group B8	Day 22	1.81	94.0	1.7	0.9	1.700	0.530	0.00	31.19	0.0	86.2	3.18	1.700
B0125	Group B7	Day 1	0.11	80.8	7.7	7.7	0.085	0.008	0.01	9.52	14.3	0.0	0.08	
B0125	Group B7	Day 22	0.14	63.6	21.2	3.0	0.087	0.017	0.02	19.05	19.0	0.0	0.18	0.002 1.027
B0126	Group B3	Day 1	0.06	67.6	20.6	0.0	0.043	0.002	0.00	4.35	4.3	0.0	0.04	
B0126	Group B3	Day 22	1.01	85.4	11.1	0.0	0.866	0.079	0.06	9.09	7.2	25.3	0.25	0.823 20.035
B0127	Group B9	Day 1	0.19	69.0	26.8	0.0	0.133	0.008	0.01	6.12	4.1	4.1	0.07	
B0127	Group B9	Day 22	1.10	68.9	28.1	0.0	0.759	0.052	0.03	6.85	3.4	37.7	0.16	0.626 5.697
B0129	Group B8	Day 1	0.06	50.0	50.0	0.0	0.029	0.000	0.00	0.00	0.0	0.0	0.03	
B0129	Group B8	Day 22	3.15	92.9	3.1	0.4	2.922	0.161	0.01	5.51	0.4	76.3	0.35	2.893 101.577
B0131	Group B8	Day 1	0.06	65.4	15.4	3.8	0.038	0.009	0.00	23.53	0.0	17.6	0.04	
B0131	Group B8	Day 22	0.90	95.7	3.7	0.2	0.859	0.041	0.01	4.76	1.1	74.8	0.06	0.821 22.573
B0134	Group B3	Day 1	0.20	75.0	16.7	4.2	0.150	0.050	0.02	33.33	11.1	27.8	0.08	
B0134	Group B3	Day 22	1.45	94.2	2.9	0.6	1.362	0.084	0.08	6.17	6.2	66.0	0.12	1.211 9.054
B0135	Group B7	Day 1	0.06	70.4	11.1	7.4	0.042	0.004	0.00	10.53	0.0	5.3	0.04	
B0135	Group B7	Day 22	0.07	84.8	9.1	0.0	0.059	0.008	0.00	14.29	3.6	10.7	0.04	0.018 1.427

Administration Site Key: FA = Forearm; UA= Upper arm

Treatments Part A: A1 = A/Sing MAP, 15 ug (FA); A2 = Afluria Quad IM (UA), 15 ug; A3 = Placebo MAP (FA); A4 = A/Sing Mono IM, 15 ug (UA)

Treatments Part B: B1 = A/Sing MAP, 15 ug (FA) with biopsy; B2 = Placebo MAP (FA) with biopsy

B3 = A/Sing MAP, 15 ug (FA); B4 = A/Sing MAP, 10 ug (FA); B5 = A/Sing MAP, 5 ug (FA); B6 = A/Sing MAP, 2.5 ug (FA)

B7 = Placebo MAP (FA); B8 = A/Sing MAP, 15 ug (UA); B9 = A/Sing IM, 15 ug, as 2018 Afluria Quad (UA)

Listing 16.2.6.5
Immunogenicity Results (Memory B Cells)

Part B

Randomi- sation Number	Group	Visit	MI TOTAL				MI IgG+	MI IgG+	MI IgG+	%stem cross	%NC99 cross	%CD27+Cd2 1-	%stem	Delta (D22-D1)	Fold (D22/D1)
			IgD- %	IgG%	IgA%	IgM%		stem	NC99+					MI IgG+	MI IgG+
B0136	Group B9	Day 1	0.19	53.8	0.0	0.0	0.105	0.015	0.00	14.29	0.0	0.0	0.00		
B0136	Group B9	Day 22	0.41	65.9	34.1	0.0	0.269	0.037	0.00	13.79	0.0	41.4	0.23	0.164	2.562
B0137	Group B8	Day 1	0.05	28.6	57.1	14.3	0.014	0.000	0.00	0.00	0.0	50.0	0.04		
B0137	Group B8	Day 22	1.91	86.6	3.6	0.2	1.655	0.048	0.05	2.90	2.9	48.8	0.09	1.640	114.197
B0138	Group B7	Day 1	0.18	12.1	3.0	66.7	0.022	0.000	0.01	0.00	25.0	0.0	0.03		
B0138	Group B7	Day 22	0.13	38.7	0.0	45.2	0.051	0.004	0.00	8.33	8.3	16.7	0.04	0.029	2.313
B0140	Group B9	Day 1	0.22	81.8	4.5	0.0	0.176	0.049	0.00	27.78	0.0	11.1	0.08		
B0140	Group B9	Day 22	0.35	65.1	16.3	0.0	0.227	0.032	0.01	14.29	3.6	42.9	0.11	0.050	1.286
B0141	Group B3	Day 1	0.04	33.3	0.0	0.0	0.013	0.000	0.00	0.00	0.0	0.0	0.03		
B0141	Group B3	Day 22	0.95	77.7	12.8	2.1	0.739	0.486	0.01	65.75	1.4	69.9	1.07	0.726	56.992
B0145	Group B3	Day 1	0.07	71.4	14.3	0.0	0.052	0.000	0.01	0.00	10.0	0.0	0.05		
B0145	Group B3	Day 22	1.18	74.9	4.3	0.8	0.884	0.139	0.03	15.72	3.0	61.9	0.29	0.832	16.964
B0146	Group B7	Day 1	0.02	40.0	60.0	0.0	0.008	0.000	0.00	0.00	0.0	0.0	0.01		
B0146	Group B7	Day 22	0.05	15.4	30.8	7.7	0.008	0.000	0.00	0.00	0.0	0.0	0.00	0.001	1.072
B0147	Group B9	Day 1	0.07	50.0	30.0	10.0	0.033	0.007	0.00	20.00	0.0	20.0	0.23		
B0147	Group B9	Day 22	0.32	75.8	9.1	3.0	0.239	0.172	0.03	72.00	12.0	44.0	0.43	0.206	7.272

Administration Site Key: FA = Forearm; UA= Upper arm

Treatments Part A: A1 = A/Sing MAP, 15 ug (FA); A2 = Afluria Quad IM (UA), 15 ug; A3 = Placebo MAP (FA); A4 = A/Sing Mono IM, 15 ug (UA)

Treatments Part B: B1 = A/Sing MAP, 15 ug (FA) with biopsy; B2 = Placebo MAP (FA) with biopsy

B3 = A/Sing MAP, 15 ug (FA); B4 = A/Sing MAP, 10 ug (FA); B5 = A/Sing MAP, 5 ug (FA); B6 = A/Sing MAP, 2.5 ug (FA)

B7 = Placebo MAP (FA); B8 = A/Sing MAP, 15 ug (UA); B9 = A/Sing IM, 15 ug, as 2018 Afluria Quad (UA)

Listing 16.2.6.5
Immunogenicity Results (Memory B Cells)

Part B

Randomi- sation Number	Group	Visit	MI TOTAL		IgA%	IgM%	MI IgG+	MI IgG+ stem	MI IgG+ NC99+	%stem cross	%NC99 cross	%CD27+Cd2 1-	%stem	Delta (D22-D1)	Fold (D22/D1)
			IgD- %	IgG%										MI IgG+	MI IgG+
B0149	Group B8	Day 1	0.09	62.5	6.3	0.0	0.056	0.000	0.00	0.00	0.0	10.0	0.02		
B0149	Group B8	Day 22	4.78	88.6	5.0	0.2	4.233	0.034	0.09	0.81	2.1	73.0	0.08	4.177	75.694
B1019	Group B8	Day 1	0.04	83.3	4.2	0.0	0.035	0.002	0.00	5.00	5.0	15.0	0.19		
B1019	Group B8	Day 22	0.96	95.2	3.6	0.5	0.911	0.043	0.05	4.76	5.9	52.1	0.22	0.876	26.289
B1080	Group B7	Day 1	0.08	78.7	8.5	8.5	0.064	0.021	0.01	32.43	8.1	5.4	0.10		
B1080	Group B7	Day 22	0.12	60.4	20.8	2.1	0.073	0.008	0.00	10.34	0.0	6.9	0.11	0.009	1.137

Administration Site Key: FA = Forearm; UA= Upper arm

Treatments Part A: A1 = A/Sing MAP, 15 ug (FA); A2 = Afluria Quad IM (UA), 15 ug; A3 = Placebo MAP (FA); A4 = A/Sing Mono IM, 15 ug (UA)

Treatments Part B: B1 = A/Sing MAP, 15 ug (FA) with biopsy; B2 = Placebo MAP (FA) with biopsy

B3 = A/Sing MAP, 15 ug (FA); B4 = A/Sing MAP, 10 ug (FA); B5 = A/Sing MAP, 5 ug (FA); B6 = A/Sing MAP, 2.5 ug (FA)

B7 = Placebo MAP (FA); B8 = A/Sing MAP, 15 ug (UA); B9 = A/Sing IM, 15 ug, as 2018 Afluria Quad (UA)